Point72 Asia Singapore Pte. Ltd. Boosts Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Point72 Asia Singapore Pte. Ltd. boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 59.6% during the 2nd quarter, Holdings Channel reports. The firm owned 2,724 shares of the company’s stock after acquiring an additional 1,017 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Cellebrite DI were worth $33,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quadrature Capital Ltd purchased a new position in Cellebrite DI in the fourth quarter worth $2,222,000. Capstone Investment Advisors LLC purchased a new position in shares of Cellebrite DI during the 1st quarter valued at $870,000. Sei Investments Co. lifted its position in shares of Cellebrite DI by 44.7% during the 1st quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock valued at $1,343,000 after buying an additional 37,408 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Cellebrite DI by 7.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company’s stock valued at $56,446,000 after buying an additional 514,858 shares during the last quarter. Finally, Inspire Investing LLC purchased a new position in shares of Cellebrite DI during the 1st quarter valued at $862,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft upped their price target on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 16th. TD Cowen upped their price target on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Craig Hallum boosted their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Bank of America boosted their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $18.57.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $16.52 on Wednesday. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -28.48, a PEG ratio of 2.32 and a beta of 1.52. The business’s fifty day moving average is $15.69 and its 200 day moving average is $12.90. Cellebrite DI Ltd. has a 52-week low of $6.36 and a 52-week high of $17.82.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.05 EPS. Equities analysts predict that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.